美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

亞盛醫藥

40.73

-0.3300-0.80%

成交量：2,511.00

成交額：10.21萬

市值：37.95億

市盈率：-55.37

高：40.98

開：40.98

低：40.34

收：41.06

52周最高：48.45

52周最低：16.50

股本：9,316.78萬

流通股本：7,158.28萬

量比：0.49

換手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-0.7356

每股收益(LYR):-0.7356

淨資產收益率：-159.65%

總資產收益率：-22.77%

市淨率：40.57

市盈率(LYR):-55.37

資料載入中...

總覽公司新聞公告

亞盛醫藥5月27日成交額為44.74萬美元

股價上漲超 200%，亞盛醫藥的“抗寒”秘訣是什麼？

Insight数据库

【ASCO 2025】亞盛醫藥Bcl-2抑制劑Lisaftoclax獲口頭報告，針對維奈克拉治療失敗患者呈現臨牀潛力

亞盛醫藥-B現漲超7% 將於2025 ASCO年會上公佈包含Lisaftoclax在內的兩項臨牀最新進展

亞盛醫藥將在美國腫瘤學會年會展示新臨牀研究進展

港股異動 | 亞盛醫藥-B(06855)高開近4% 將於2025 ASCO年會上公佈包含Lisaftoclax在內的兩項臨牀最新進展

亞盛醫藥5月22日成交額為30.34萬美元

【亞盛醫藥-B(06855.HK)：將在2025年美國臨牀腫瘤學會年會公佈兩項最新臨牀進展，其中Lisaftoclax獲口頭報告】亞盛醫藥-B(06855.HK)發佈公告，公司將在2025年5月30日至2025年6月3日在美國伊利諾伊州芝加哥舉辦的2025年美國臨牀腫瘤學會(ASCO) 年會上，分別以口頭報告和壁報形式公佈APG-2575 (lisaftoclax)治療多種血液系統腫瘤和APG-115 (alrizomadlin)治療實體瘤的臨牀研究最新進展。這兩項臨牀研究的最新數據表明lisaftoclax和alrizomadlin均具有潛在的抗腫瘤活性，且將支持對這兩個品種的進一步臨牀開發。

亞盛醫藥-B(06855)：將在2025年美國臨牀腫瘤學會年會公佈兩項最新臨牀進展，其中Lisaftoclax獲口頭報告

亞盛醫藥：將在2025年美國臨牀腫瘤學會年會公佈兩項最新臨牀進展，其中Lisaftoclax獲口頭報告

亞盛醫藥5月21日成交額為49.92萬美元

港股醫藥股延續漲勢，亞盛醫藥-B漲超10%

南方财经网

亞盛醫藥5月19日成交額為5.11萬美元

亞盛醫藥上漲5.3%，報23.85美元/股，總市值20.78億美元

亞盛醫藥5月16日成交額為10.99萬美元

亞盛醫藥上漲3.26%，報23.29美元/股，總市值20.29億美元

亞盛醫藥5月14日成交額為39.22萬美元

亞盛醫藥5月13日成交額為58.62萬美元

亞盛醫藥5月12日成交額為27.03萬美元

亞盛醫藥5月8日成交額為6.54萬美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AAPG/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亞盛醫藥","latestPrice":40.73,"timestamp":1757432071234,"preClose":41.06,"halted":0,"volume":2511,"delay":0,"floatShares":71582800,"shares":93167803,"eps":-0.735552,"marketStatus":"交易中","change":-0.33,"latestTime":"09-09 11:50:23 EDT","open":40.98,"high":40.98,"low":40.3391,"amount":102124.243206,"amplitude":0.015609,"askPrice":40.78,"askSize":1000,"bidPrice":40.37,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1757448000000},"marketStatusCode":2,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":41.06,"postHourTrading":{"tag":"盘后","latestPrice":41.04,"preClose":41.04,"latestTime":"16:10 EDT","volume":2,"amount":82.12,"timestamp":1757362203755},"volumeRatio":0.487719},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":0.487719,"shares":93167803,"dividePrice":0,"high":40.98,"amplitude":0.015609,"preClose":41.06,"low":40.3391,"week52Low":16.5,"pbRate":"40.57","psRate":"69.18","week52High":48.45,"institutionHeld":0,"latestPrice":40.73,"committee":-0.333333,"eps":-0.735552,"divideRate":0,"volume":2511,"delay":0,"ttmEps":-0.735552,"open":40.98,"prevYearClose":17.25,"prevWeekClose":40.4987,"prevMonthClose":42.47,"prevQuarterClose":39.375,"fiveDayClose":41.82,"twentyDayClose":40.04,"sixtyDayClose":32.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盤前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743825600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2025-09-08","current":-23.478386,"percent":0.980392,"low":-76.454813,"twenty":-59.602544,"median":-36.307775,"eighty":-31.810921,"high":-21.702816,"avg":-42.462654,"sd":14.204425,"marketCap":3817512539.24},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-08","current":-23.478386,"twenty":-59.602544,"median":-36.307775,"eighty":-31.810921,"marketCap":3817512539.24}],"updateTime":1757410727136},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538041672","title":"亞盛醫藥5月27日成交額為44.74萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2538041672","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538041672?lang=zh_tw&edition=fundamental","pubTime":"2025-05-28 09:15","pubTimestamp":1748394914,"startTime":"0","endTime":"0","summary":"美东时间2025年5月27日，亚盛医药成交额为44.74万美元，成交额较昨日减少16.10%，当日成交量为1.74万股。亚盛医药于2025年5月27日跌2.51%，报25.82美元，该股过去5个交易日涨8.56%，年初至今涨49.65%，过去60日涨35.65%。它专注于开发抑制蛋白质间相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。该公司的地理部门包括美国和中国大陆。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528091535a6ef8f89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528091535a6ef8f89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2538141169","title":"股價上漲超 200%，亞盛醫藥的“抗寒”秘訣是什麼？","url":"https://stock-news.laohu8.com/highlight/detail?id=2538141169","media":"Insight数据库","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538141169?lang=zh_tw&edition=fundamental","pubTime":"2025-05-26 07:31","pubTimestamp":1748215883,"startTime":"0","endTime":"0","summary":"5 月 23 日，港股收盘价显示，亚盛医药股价为50.55 元，总市值 176 亿港元。与彼时相比，亚盛今日的股价累计涨幅已高达228%。而这一局面在 2024 年 6 月亚盛与武田达成被业界誉为“史诗级 BD 大单”的战略合作后迎来关键转折。消息落地当日，资本市场迅速作出积极反应，亚盛医药股价单日暴涨 17%。增长基石216% 的股价增长或许只是起点，亚盛医药的研发实力才是其长期价值的核心支撑。维奈克拉作为全球首款上市 的 BCL-2","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250526081820a48c37a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250526081820a48c37a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06855","AAPG"],"gpt_icon":0},{"id":"2537906445","title":"【ASCO 2025】亞盛醫藥Bcl-2抑制劑Lisaftoclax獲口頭報告，針對維奈克拉治療失敗患者呈現臨牀潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=2537906445","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537906445?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 10:51","pubTimestamp":1747968660,"startTime":"0","endTime":"0","summary":"Bcl-2抑制剂lisaftoclax和MDM2-p53抑制剂alrizomadlin均为亚盛医药细胞凋亡管线重点品种。在研新型口服选择性Bcl-2抑制剂lisaftoclax联合阿扎胞苷已在既往临床前和临床研究中显示强劲疗效。数据表明，lisaftoclax联合阿扎胞苷的耐受性良好并已显示初步疗效。仅有3%的患者因中性粒细胞减少下调了lisaftoclax的剂量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4694966_ZH94966_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00B3T34201.USD","LU1571399168.USD","CR","NCI","BK4566","LU1291159041.SGD","LU1116320901.HKD","IE00BQXX3D17.EUR","BK4585","LU0070302665.USD","LU1116320737.USD","LU2089284900.SGD","ORR","BK1574","06855","LU1989764748.USD","LU0162691827.USD","LU2111349929.HKD","LU1983299246.USD","AAPG","PFS","IE00BQXX3F31.USD","LU0158827948.USD","LU2089283258.USD","LU2089984988.USD","LU0208291251.USD","IE00BFXG1179.USD","LU0072461881.USD","BK4533","BK4017","LU2028103732.USD","IE00BQXX3C00.GBP","BK4161","SD","BK4082","BK4588","TRAE","CDE","BK1161","BK4213","LU2023251221.USD","LU0320765489.SGD","MDT","LU0211326839.USD","BTC","BK4211","LU0265550359.USD","LU1989764664.SGD","LU0496365809.HKD"],"gpt_icon":0},{"id":"2537297442","title":"亞盛醫藥-B現漲超7% 將於2025 ASCO年會上公佈包含Lisaftoclax在內的兩項臨牀最新進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2537297442","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537297442?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 09:40","pubTimestamp":1747964400,"startTime":"0","endTime":"0","summary":"　　亚盛医药-B早盘高开，股价上涨7.18%，现报52.25港元，成交额6661.76万港元。　　亚盛医药-B发布公告，公司将在2025年5月30日至2025年6月3日在美国伊利诺伊州芝加哥举办的2025年美国临床肿瘤学会年会上，分别以口头报告和壁报形式公布APG-2575治疗多种血液系统肿瘤和APG-115治疗实体瘤的临床研究最新进展。这两项临床研究的最新数据表明lisaftoclax和alrizomadlin均具有潜在的抗肿瘤活性，且将支持对这两个品种的进一步临床开发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-05-23/doc-inexpeuk8941116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","AAPG","BK1161","BK4139","06855"],"gpt_icon":0},{"id":"2537974130","title":"亞盛醫藥將在美國腫瘤學會年會展示新臨牀研究進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2537974130","media":"财中社","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537974130?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 09:36","pubTimestamp":1747964191,"startTime":"0","endTime":"0","summary":"5月23日，亚盛医药发布公告，宣布公司将在2025年5月30日至6月3日于美国芝加哥举办的2025年美国临床肿瘤学会年会上，展示两项最新的临床研究进展。APG-115的研究则涉及54例晚期腺样囊性癌等患者，初步结果显示该药物具有可控的安全性和抗肿瘤活性。此次公告突显了公司在肿瘤治疗领域的积极进展，尤其是lisaftoclax在急性髓系白血病和骨髓增生异常综合症患者中的治疗潜力，预计将推动对这两种药物的进一步临床开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052309373694ffc4f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052309373694ffc4f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2537097144","title":"港股異動 | 亞盛醫藥-B(06855)高開近4% 將於2025 ASCO年會上公佈包含Lisaftoclax在內的兩項臨牀最新進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2537097144","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537097144?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 09:25","pubTimestamp":1747963505,"startTime":"0","endTime":"0","summary":"消息面上，亚盛医药-B发布公告，公司将在2025年5月30日至2025年6月3日在美国伊利诺伊州芝加哥举办的2025年美国临床肿瘤学会年会上，分别以口头报告和壁报形式公布APG-2575治疗多种血液系统肿瘤和APG-115治疗实体瘤的临床研究最新进展。这两项临床研究的最新数据表明lisaftoclax和alrizomadlin均具有潜在的抗肿瘤活性，且将支持对这两个品种的进一步临床开发。此项全球多中心研究入组患者近百人，数据显示lisaftoclax联合阿扎胞苷的耐受性良好并已显示初步疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1296696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG","BK4139","BK1574","BK1161"],"gpt_icon":0},{"id":"2537971969","title":"亞盛醫藥5月22日成交額為30.34萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537971969","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537971969?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 09:15","pubTimestamp":1747962915,"startTime":"0","endTime":"0","summary":"美东时间2025年5月22日，亚盛医药成交额为30.34万美元，成交额较昨日减少39.21%，当日成交量为1.20万股。亚盛医药于2025年5月22日涨1.75%，报25.56美元，该股过去5个交易日涨13.3%，年初至今涨48.17%，过去60日涨23.66%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-22|30.34万|-39.21%|1.20万|#|2025-05-21|49.92万|547.12%|2.00万|#|2025-05-20|7.71万|51.00%|3331.00|#|2025-05-19|5.11万|-53.53%|2167.00|#|2025-05-16|10.99万|-42.18%|4835.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523091529a6e98450&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523091529a6e98450&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2537297576","title":"【亞盛醫藥-B(06855.HK)：將在2025年美國臨牀腫瘤學會年會公佈兩項最新臨牀進展，其中Lisaftoclax獲口頭報告】亞盛醫藥-B(06855.HK)發佈公告，公司將在2025年5月30日至2025年6月3日在美國伊利諾伊州芝加哥舉辦的2025年美國臨牀腫瘤學會(ASCO) 年會上，分別以口頭報告和壁報形式公佈APG-2575 (lisaftoclax)治療多種血液系統腫瘤和APG-115 (alrizomadlin)治療實體瘤的臨牀研究最新進展。這兩項臨牀研究的最新數據表明lisaftoclax和alrizomadlin均具有潛在的抗腫瘤活性，且將支持對這兩個品種的進一步臨牀開發。","url":"https://stock-news.laohu8.com/highlight/detail?id=2537297576","media":"金融界","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537297576?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 08:07","pubTimestamp":1747958827,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855.HK)发布公告，公司将在2025年5月30日至2025年6月3日在美国伊利诺伊州芝加哥举办的2025年美国临床肿瘤学会(ASCO) 年会上，分别以口头报告和壁报形式公布APG-2575 (lisaftoclax)治疗多种血液系统肿瘤和APG-115 (alrizomadlin)治疗实体瘤的临床研究最新进展。这两项临床研究的最新数据表明lisaftoclax和alrizomadlin均具有潜在的抗肿瘤活性，且将支持对这两个品种的进一步临床开发。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/23080750603136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK4139","LU1923622291.USD","06855","BK1574","LU2125909916.SGD","LU2125909759.SGD","APG","BK4129","AAPG"],"gpt_icon":0},{"id":"2537754409","title":"亞盛醫藥-B(06855)：將在2025年美國臨牀腫瘤學會年會公佈兩項最新臨牀進展，其中Lisaftoclax獲口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2537754409","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537754409?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 08:04","pubTimestamp":1747958646,"startTime":"0","endTime":"0","summary":"Bcl-2抑制剂lisaftoclax和MDM2-p53抑制剂alrizomadlin均为亚盛细胞凋亡管线重点品种。此次lisaftoclax获选口头报告的研究为一项该品种联合阿扎胞苷治疗初治或既往接受过维奈克拉治疗的髓系恶性肿瘤患者的1b/2期临床研究。此项全球多中心研究入组患者近百人，数据显示lisaftoclax联合阿扎胞苷的耐受性良好并已显示初步疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1296661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药-B(06855)：将在2025年美国临床肿瘤学会年会公布两项最新临床进展，其中Lisaftoclax获口头报告","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06855","BK1161","AAPG","BK4139"],"gpt_icon":0},{"id":"2537765609","title":"亞盛醫藥：將在2025年美國臨牀腫瘤學會年會公佈兩項最新臨牀進展，其中Lisaftoclax獲口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2537765609","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537765609?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 08:04","pubTimestamp":1747958640,"startTime":"0","endTime":"0","summary":"亚盛医药将在2025年美国临床肿瘤学会年会上公布APG-2575和APG-115两种药物的最新临床进展，数据显示两者均具抗肿瘤活性，支持进一步开发。其中，lisaftoclax治疗髓系恶性肿瘤的联合疗法数据首次公布，显示良好疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505230815309762816b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505230815309762816b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2537966887","title":"亞盛醫藥5月21日成交額為49.92萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537966887","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537966887?lang=zh_tw&edition=fundamental","pubTime":"2025-05-22 09:15","pubTimestamp":1747876513,"startTime":"0","endTime":"0","summary":"美东时间2025年5月21日，亚盛医药成交额为49.92万美元，成交额较昨日增加547.12%，当日成交量为2.00万股。亚盛医药于2025年5月21日涨9.22%，报25.12美元，该股过去5个交易日涨7.35%，年初至今涨45.62%，过去60日涨24.6%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-21|49.92万|547.12%|2.00万|#|2025-05-20|7.71万|51.00%|3331.00|#|2025-05-19|5.11万|-53.53%|2167.00|#|2025-05-16|10.99万|-42.18%|4835.00|#|2025-05-15|19.01万|-51.52%|8364.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522091522a6e81686&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522091522a6e81686&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2537676559","title":"港股醫藥股延續漲勢，亞盛醫藥-B漲超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537676559","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537676559?lang=zh_tw&edition=fundamental","pubTime":"2025-05-21 10:24","pubTimestamp":1747794269,"startTime":"0","endTime":"0","summary":"南方财经5月21日电，港股医药股延续涨势，亚盛医药-B涨超10%，康方生物涨超7%，金斯瑞生物科技、微创医疗涨逾6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"81e47d774545ba217a24feab6560fced","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505213410495480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06855","BK1574","BK4139","AAPG","BK1161"],"gpt_icon":0},{"id":"2536269654","title":"亞盛醫藥5月19日成交額為5.11萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536269654","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536269654?lang=zh_tw&edition=fundamental","pubTime":"2025-05-20 09:15","pubTimestamp":1747703712,"startTime":"0","endTime":"0","summary":"美东时间2025年5月19日，亚盛医药成交额为5.11万美元，成交额较昨日减少53.53%，当日成交量为2167.00股。亚盛医药于2025年5月19日涨4.99%，报23.78美元，该股过去5个交易日跌1.74%，年初至今涨37.86%，过去60日涨12.33%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-19|5.11万|-53.53%|2167.00|#|2025-05-16|10.99万|-42.18%|4835.00|#|2025-05-15|19.01万|-51.52%|8364.00|#|2025-05-14|39.22万|-33.10%|1.66万|#|2025-05-13|58.62万|116.86%|2.44万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520091527a6e557be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520091527a6e557be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2536631258","title":"亞盛醫藥上漲5.3%，報23.85美元/股，總市值20.78億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536631258","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536631258?lang=zh_tw&edition=fundamental","pubTime":"2025-05-20 01:21","pubTimestamp":1747675277,"startTime":"0","endTime":"0","summary":"5月20日，亚盛医药盘中上涨5.3%，截至01:21，报23.85美元/股，成交1.62万美元，总市值20.78亿美元。财务数据显示，截至2024年12月31日，亚盛医药收入总额9.81亿人民币，同比增长341.77%；归母净利润-4.05亿人民币，同比增长56.2%。目前公司正在中国、美国、澳大利亚及欧洲开展40多项临床试验。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052001321594fbbc2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052001321594fbbc2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2536455378","title":"亞盛醫藥5月16日成交額為10.99萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536455378","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536455378?lang=zh_tw&edition=fundamental","pubTime":"2025-05-17 09:15","pubTimestamp":1747444513,"startTime":"0","endTime":"0","summary":"美东时间2025年5月16日，亚盛医药成交额为10.99万美元，成交额较昨日减少42.18%，当日成交量为4835.00股。亚盛医药于2025年5月16日涨0.42%，报22.65美元，该股过去5个交易日跌6.83%，年初至今涨31.3%，过去60日涨15.15%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-16|10.99万|-42.18%|4835.00|#|2025-05-15|19.01万|-51.52%|8364.00|#|2025-05-14|39.22万|-33.10%|1.66万|#|2025-05-13|58.62万|116.86%|2.44万|#|2025-05-12|27.03万|12.93%|1.14万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517091519a481858e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517091519a481858e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2536445783","title":"亞盛醫藥上漲3.26%，報23.29美元/股，總市值20.29億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536445783","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536445783?lang=zh_tw&edition=fundamental","pubTime":"2025-05-17 02:39","pubTimestamp":1747420769,"startTime":"0","endTime":"0","summary":"5月17日，亚盛医药盘中上涨3.26%，截至02:39，报23.29美元/股，成交7.68万美元，总市值20.29亿美元。财务数据显示，截至2024年12月31日，亚盛医药收入总额9.81亿人民币，同比增长341.77%；归母净利润-4.05亿人民币，同比增长56.2%。目前,耐立克已被成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录》。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/17023950465868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2535509836","title":"亞盛醫藥5月14日成交額為39.22萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535509836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535509836?lang=zh_tw&edition=fundamental","pubTime":"2025-05-15 09:15","pubTimestamp":1747271716,"startTime":"0","endTime":"0","summary":"美东时间2025年5月14日，亚盛医药成交额为39.22万美元，成交额较昨日减少33.10%，当日成交量为1.66万股。亚盛医药于2025年5月14日跌2.66%，报23.4美元，该股过去5个交易日跌3.19%，年初至今涨35.65%，过去60日涨26.42%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-14|39.22万|-33.10%|1.66万|#|2025-05-13|58.62万|116.86%|2.44万|#|2025-05-12|27.03万|12.93%|1.14万|#|2025-05-09|23.94万|265.94%|9839.00|#|2025-05-08|6.54万|-91.95%|2663.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515091529a6dfa417&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515091529a6dfa417&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2535537520","title":"亞盛醫藥5月13日成交額為58.62萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535537520","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535537520?lang=zh_tw&edition=fundamental","pubTime":"2025-05-14 09:15","pubTimestamp":1747185313,"startTime":"0","endTime":"0","summary":"美东时间2025年5月13日，亚盛医药成交额为58.62万美元，成交额较昨日增加116.86%，当日成交量为2.44万股。亚盛医药于2025年5月13日跌0.66%，报24.04美元，该股过去5个交易日跌6.82%，年初至今涨39.36%，过去60日涨31.8%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-13|58.62万|116.86%|2.44万|#|2025-05-12|27.03万|12.93%|1.14万|#|2025-05-09|23.94万|265.94%|9839.00|#|2025-05-08|6.54万|-91.95%|2663.00|#|2025-05-07|81.21万|-15.78%|3.35万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514091519a6de366c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514091519a6de366c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2535779575","title":"亞盛醫藥5月12日成交額為27.03萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535779575","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535779575?lang=zh_tw&edition=fundamental","pubTime":"2025-05-13 09:15","pubTimestamp":1747098912,"startTime":"0","endTime":"0","summary":"美东时间2025年5月12日，亚盛医药成交额为27.03万美元，成交额较昨日增加12.93%，当日成交量为1.14万股。亚盛医药于2025年5月12日跌0.45%，报24.2美元，该股过去5个交易日跌4.35%，年初至今涨40.29%，过去60日涨40.21%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-12|27.03万|12.93%|1.14万|#|2025-05-09|23.94万|265.94%|9839.00|#|2025-05-08|6.54万|-91.95%|2663.00|#|2025-05-07|81.21万|-15.78%|3.35万|#|2025-05-06|96.43万|188.56%|3.75万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250513091524a6dcd714&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250513091524a6dcd714&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2534900741","title":"亞盛醫藥5月8日成交額為6.54萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534900741","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534900741?lang=zh_tw&edition=fundamental","pubTime":"2025-05-09 09:15","pubTimestamp":1746753313,"startTime":"0","endTime":"0","summary":"美东时间2025年5月8日，亚盛医药成交额为6.54万美元，成交额较昨日减少91.95%，当日成交量为2663.00股。亚盛医药于2025年5月8日涨4.11%，报25.16美元，该股过去5个交易日涨0.04%，年初至今涨45.86%，过去60日涨38.01%。它专注于开发抑制蛋白质间相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。该公司的地理部门包括美国和中国大陆。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509091521a6d85fa2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509091521a6d85fa2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":6,"totalSize":172,"code":"91000000","status":"200"}]}}